Overview
Swedish biotech firm reports Q4 revenue of SEK 5.5 mln
Company entered exclusive license agreement with Biossil for remetinostat
Outlook
Medivir plans to initiate clinical development of MIV-711 for Osteogenesis Imperfecta
Company aims to conduct randomized study of fostrox for liver cancer
Medivir expects clinical results for MIV-701 study in Q4 2026
Result Drivers
FINANCIAL STRENGTH - Rights issue raised SEK 151 mln, bolstering financial position for ongoing clinical developments
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 5.50 mln
Q4 Adjusted EBITDA
-SEK 12 mln
Q4 Adjusted Free Cash Flow
-SEK 6.30 mln
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Medivir AB is SEK4.00, about 300% above its February 17 closing price of SEK1.00
Press Release: ID:nMFN2vWCcx
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
